Sign In
Buy LLY
$1,231.58
+45.87 (+3.87%)
At Close: Aug 10, 2026
Eli Lilly to buy genetic medicine developer Akouos for $487 million
07:05am, Tuesday, 18'th Oct 2022
Drugmaker Eli Lilly and Co will acquire genetic medicine developer Akouos Inc in a cash deal worth about $487 million.
Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss
07:01am, Tuesday, 18'th Oct 2022
Eli Lilly and Co. LLY, +0.41% said Tuesday it has entered an agreement to acquire Akouos Inc. AKUS, -5.14% , a company developing a portfolio of viral gene therapies for the treatment of inner ear con
Best Healthcare Stocks To Invest In Today? 2 Names To Watch
04:33pm, Friday, 14'th Oct 2022
Should investors be turning their attention to these large-cap healthcare stocks right now?
These Were The Five Best And Worst Performing Mega-Cap Stocks In Q3 2022
07:50pm, Thursday, 13'th Oct 2022
The third quarter started with a relief rally, but the end was consistent with the performance of the first two quarters.
What's Next For Eli Lilly Stock After Nearly A 3x Rise Since 2018?
11:08am, Wednesday, 12'th Oct 2022
Eli Lilly stock (NYSE: LLY) has seen a 21% rise this year, significantly outperforming the broader S&P500 index, down 21%.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
10:32am, Wednesday, 12'th Oct 2022
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Amgen, The Big Name You Need To Know Going Up Against Novo, Lilly In Obesity
01:43pm, Tuesday, 11'th Oct 2022
Amgen stock surged Tuesday on a reportedly bullish call for its experimental obesity treatment — a potential rival to Novo and Lilly. The post Amgen, The Big Name You Need To Know Going Up Against N
What's Next For Eli Lilly Stock After Nearly A 3x Rise Since 2018?
10:00am, Monday, 10'th Oct 2022
Eli Lilly stock (NYSE: LLY) has seen a 21% rise this year, significantly outperforming the broader S&P500 index, down 21%.
These 7 Biotech Stocks Are Set to Boom in 2023
06:15am, Monday, 10'th Oct 2022
Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good
Eli Lilly Leads 5 Stocks To Watch In Bear Market
08:00am, Saturday, 08'th Oct 2022
Cardinal Health and Eli Lilly lead five stocks to watch. Some are holding up while others crumbled Friday amid the bear market.
Lilly's (LLY) Diabetes Drug Gets FDA Fast Track Tag for Obesity
12:48pm, Friday, 07'th Oct 2022
Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.
Bank of American: Lilly's tirzepatide could be the first $100 billion drug
10:31am, Friday, 07'th Oct 2022
Bank of America analysts on Friday told investors that Eli Lilly & Co. Inc.'s LLY, -0.93% diabetes treatment and possible weight-management drug could be a $100 billion medication. The drug, tirzepati
4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire
06:25am, Friday, 07'th Oct 2022
This quartet of stocks has plenty of growth ahead and is already profitable.
FDA ‘fast tracks' Eli Lilly's obesity drug: ‘this is the Holy Grail'
05:15pm, Thursday, 06'th Oct 2022
Eli Lilly & Co (NYSE: LLY) is in focus on Thursday after the pharmaceutical giant said the U.S. FDA agreed to a speedy review of Tirzepatide for the treatment of obesity and weight-related comorbiditi
Eli Lilly's experimental obesity drug could be 'revolutionary,' says Jim Cramer
11:22am, Thursday, 06'th Oct 2022
CNBC's Jim Cramer and the 'Squawk on the Street' team discuss shares of Eli Lilly after the U.S. Food and Drug Administration granted the company a fast-track designation for its obesity drug.
